The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
The BioCentury Show
Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
Since the annual J.P. Morgan Healthcare Conference in San Francisco in early January, biotech has seen a notable surge in enthusiasm, Zahid Moneer, senior managing director of investment banking at BNP Paribas, told The BioCentury Show.
Moneer, who is more upbeat than many in today’s biopharma sector, sees capital raises from million-dollar seed rounds to nine-digit series A, B, and C rounds driving significant growth alongside M&A activity. In the interview, he also also highlights the growing role of private equity firms in biopharma and the trend of pharmas engaging earlier with biotechs and investors looking to deploy capital into those companies
View full story: https://www.biocentury.com/article/655216
#biotech #biopharma #pharma #lifescience #financing #privateequity #IPO
00:00 - Introduction
00:37 - Investment Climate
05:06 - Pharma M&A Activity
15:25 - Private Equity's Role
21:44 - Biotech Financing
.jpg)
